Shares of Aeterna Zentaris (NASDAQ: AEZS ) were gutted on the market Monday, down 25% intraday. In this video, Motley Fool health-care analyst David Williamson takes a look at a horrendous 12-month period for the company overall, and how hanging its hopes on its drug Perifosine has resulted in disappointment after disappointment in clinical trials.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.
No comments:
Post a Comment